Largest Phase III Trial of Novel Treatment for Hypertension Shows Promising Results

Hypertension: New drug shows strong results in managing blood pressure

A novel treatment, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in individuals with uncontrolled or resistant hypertension, a global phase 3 trial showed.

Largest Phase III trial of novel treatment for hypertension shows promising results

The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, show that lorundrostat, an aldosterone synthase inhibitor, is a safe and effective treatment for people with uncontrolled or resistant hypertension, demonstrating consistent blood pressure reductions across a large and diverse patient population. It is the largest phase three trial of an aldosterone synthase inhibitor for the…

Overcoming Barriers in Advanced Hypertension Therapy

Managing hypertension in complex patients involves navigating comorbidities, treatment inertia, and care fragmentation for optimal outcomes.

An Example of Continued Efforts to Expand the Portfolio of Antihypertensive Drugs

The nature of small molecule drugs and human metabolic variability is that effect sizes are usually modest and responses usually vary widely across the population. Some patients see little benefit, some patients have side-effects that limit use, and there is always the opportunity to find an alternative path to a new drug that can be used by those people. Separately, investors don't like risk, and tend to favor investment into development focuse…

New drug shows promise for hard-to-treat high blood pressure

A new medication called lorundrostat has shown strong potential as a treatment for people with uncontrolled or resistant high blood pressure, according to results from the Launch-HTN trial. The findings were presented at the 34th European Meeting on Hypertension and Cardiovascular Protection and represent a major step forward in the treatment of a condition that affects one in three […] The post New drug shows promise for hard-to-treat high bloo…

Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, showcasing the efficacy and safety of lorundrostat for patients with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). The study demonstrated significant and sustained reductions in blood pressure among over 1,000 participants who were already on two to five antihypertensive medications. Lorundrostat…